1090 The GLASS Consortium studies the evolutionary trajectories of 222 patients with a diffuse glioma to aid in our understanding of tumour progression and treatment failure.
https://www.nature.com/articles/s41586-019-1775-1
1089 Imaging and sequencing approaches are combined to show that extrachromosomal DNA (ecDNA) in cancer is circular and has unique chromatin structure that amplifies oncogene output.
https://www.nature.com/articles/s41586-019-1763-5
1088 Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
https://science.sciencemag.org/content/366/6468/1029
1087 Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.
https://www.nature.com/articles/s43018-019-0004-z
1086 Immunity to commensal papillomaviruses protects against skin cancer.
https://www.nature.com/articles/s41586-019-1719-9
1085 Mouse models of triple-negative breast cancer provide insights into how T follicular helper cell activation of B cells facilitates the effects of immune checkpoint inhibitors.
https://www.cell.com/cell/fulltext/S0092-8674(19)31178-X
1084 The Role of Non-coding RNAs in Oncology. (Review).
https://www.cell.com/cell/fulltext/S0092-8674(19)31167-5#%20
1083 An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.
https://www.pnas.org/content/116/46/23264
1082 Pan-cancer whole-genome analyses of metastatic solid tumours.
https://www.nature.com/articles/s41586-019-1689-y
1081 The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
https://www.nature.com/articles/s41586-019-1694-1
1080 Small cell lung cancer tumors are sensitive to DHODH inhibition, highlighting a potential treatment strategy for this disease.
https://stm.sciencemag.org/content/11/517/eaaw7852
1079 Some breast cancers harbor not one—but two—PIK3CA mutations, and this enhances their response to certain drugs.
https://science.sciencemag.org/content/366/6466/714
1078 The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.
https://cancerdiscovery.aacrjournals.org/content/early/2019/10/22/2159-8290.CD-19-1167
1077 n a mouse tumour model, immunotherapy-induced rejection of tumour cells requires presentation of both MHC class I and MHC class II antigens, which activate CD4+ and CD8+ T cells, respectively.
https://www.nature.com/articles/s41586-019-1671-8
1076 A highly recurrent A>C somatic mutation in U1 small nuclear RNA, which alters the splicing pattern of genes that include known drivers of cancer, is identified in several types of tumour.
https://www.nature.com/articles/s41586-019-1651-z
1075 Proteogenomic characterization of HBV-related hepatocellular carcinoma (HCC) using paired tumor and adjacent liver tissues identifies three subgroups with distinct features in metabolic reprogramming, microenvironment dysregulation, cell proliferation, and potential therapeutics.
https://www.cell.com/cell/fulltext/S0092-8674(19)31003-7
1074 PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
https://www.nature.com/articles/s41590-019-0480-4
1073 Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
https://stm.sciencemag.org/content/11/513/eaay2574
1072 Analyses of transcriptomes from patients with acute myeloid leukaemia identified frequently co-occurring mutations of IDH2 and SRSF2, which functional analyses showed to have distinct and coordinated leukaemogenic effects on the epigenome and RNA splicing.
https://www.nature.com/articles/s41586-019-1618-0
1071 Inducing and exploiting vulnerabilities for the treatment of liver cancer.
https://www.nature.com/articles/s41586-019-1607-3
|
